BioSpace News Archive

Egnyte, a leader in cloud content security and governance, will host its annual Life Sciences Summit on May 8, 2024. This year’s event will be a hybrid event, with Boston-based guests

The global CAR T-Cell Therapy Market is projected to reach USD 22.2 billion by 2032 up from USD 2.1 billion in 2023, at a CAGR of 30% from 2024-2032.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF) announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.

Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares, each representing one ordinary share, at a price to the public of $9.25 per ADS.

GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore.

The global cell-based assays market size is calculated at USD 18.25 billion in 2024 and it is increasing around USD 38.48 billion by 2033 with a CAGR of 8.64% from 2024 to 2033. U.S. cell-based assays market size was valued at USD 11.82 billion in 2023.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.

Laxxon Medical, a leading 3D screen printing platform technology company, announced today its participation in the World Orphan Drug Congress USA 2024, taking place April 23-25, 2024 in Boston, Massachusetts.

Global Third Generation Sequencing Market in terms of revenue was estimated to be worth $10.07 Bn in 2023 and is poised to reach $27.66 Bn by 2031, growing at a CAGR of 13.73% from 2024 to 2031 according to a new report by InsightAce Analytic.